Luisa Salazar‐Vizcaya
A5051313787- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- Adolescent Sexual and Reproductive Health
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Antibiotic Use and Resistance
- Sex work and related issues
- Antibiotic Resistance in Bacteria
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Pneumocystis jirovecii pneumonia detection and treatment
- Syphilis Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Folate and B Vitamins Research
- Long-Term Effects of COVID-19
- Single-cell and spatial transcriptomics
- Urinary Tract Infections Management
- Data-Driven Disease Surveillance
- Sexuality, Behavior, and Technology
University Hospital of Bern
2016-2025
University of Bern
2016-2025
McMaster University
2023-2024
Impact
2023-2024
University of Basel
2023-2024
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
University Hospital of Basel
2023-2024
Hospices Civils de Lyon
2024
University of Zurich
2024
Abstract Background. Adherence to antiretroviral therapy (ART) is crucial preventing mother-to-child transmission of human immunodeficiency virus (HIV) and ensuring the long-term effectiveness ART, yet data are sparse from African routine care programs on maternal adherence triple ART. Methods. We analyzed women who started ART at 13 large health facilities in Malawi between September 2011 October 2013. defined as percentage days “covered” by pharmacy claims. ≥90% was deemed adequate....
The incidence of hepatitis C virus (HCV) infections among human immunodeficiency (HIV)-infected men who have sex with has increased in recent years and is associated high-risk sexual behavior. Behavioral interventions that target behavior HCV transmission treatment direct-acting antivirals may prevent further infections. We predicted the effect behavioral on prevalence HIV-infected up to 2030 using a model parameterized data from Swiss HIV Cohort Study. assessed increase, stabilization,...
Abstract We followed adolescents and adults living with HIV aged older than 15 years who enrolled in a South African private-sector programme to examine adherence viral non-suppression (viral load > 400 copies/mL) of participants (20,743, 38%) without (33,635, 62%) mental health diagnoses. Mental diagnoses were associated unfavourable patterns. The risk was higher among patients organic disorders [adjusted ratio (aRR) 1.55, 95% confidence interval (CI) 1.22–1.96], substance use (aRR 1.53,...
Abstract Background Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people human immunodeficiency virus using a target trial framework, which reduces potential confounding and selection bias. Methods included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs...
The efficacy and tolerability of long-acting cabotegravir rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated an increased virologic failure. This study aims to verify whether drug measured a real-world setting are consistent those previously reported.
Abstract Background Advancements in access to antiretroviral therapy (ART) and human immunodeficiency virus (HIV) care have led a decline AIDS-related deaths among people with HIV (PWH) Switzerland. However, data on the ongoing changes causes of death PWH over past 15 years are scarce. Methods We investigated all reported Swiss Cohort Study between 2005 2022. Causes were categorized using Coding Death protocol. The statistical analysis included demographic stratification identify time trends...
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% acquired anti-IFN-I as they aged (median onset ∼63 years). Once detected, persisted lifelong, and titers increased decades. Individuals developed distinct non-neutralizing autoantibody...
Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although was observed among PWH receiving tenofovir alafenamide (TAF), little known about the potential reversibility after TAF discontinuation. We evaluated and metabolic changes 12 months discontinuation Swiss Cohort Study.
Monitoring of HIV viral load in patients on combination antiretroviral therapy (ART) is not generally available resource-limited settings. We examined the cost-effectiveness qualitative point-of-care tests (POC-VL) sub-Saharan Africa.Mathematical model based longitudinal data from Gugulethu and Khayelitsha township ART programmes Cape Town, South Africa.Cohorts monitored by POC-VL, CD4 cell count or clinically were simulated. Scenario A considered more accurate detection treatment failure...
BackgroundWHO's 2013 revisions to its Consolidated Guidelines on antiretroviral drugs recommend routine viral load monitoring, rather than clinical or immunological as the preferred monitoring approach basis of evidence. However, HIV programmes in resource-limited settings require guidance most cost-effective use resources view other competing priorities such expansion therapy coverage. We assessed cost-effectiveness alternative patient strategies.MethodsWe evaluated a range strategies,...
Tuberculosis (TB) is the leading cause of death in South Africa. The burden disease varies by age, with peaks TB notification rates HIV-negative population at ages 0-5, 20-24, and 45-49 years. There little variation between age groups HIV-positive population. drivers this pattern remain unknown.
Abstract Background The Swiss HCVree Trial (NCT 02785666) was conducted in 2015–2017 with the goal of implementing a population-based systematic hepatitis C virus (HCV) micro-elimination program among men who have sex (MSM) human immunodeficiency (HIV) enrolled HIV Cohort Study (SHCS). trial led to 91% and 77% decline HCV prevalence incidence, respectively. long-term effect this is yet be explored. Methods All MSM SHCS were screened for RNA using stored plasma samples obtained 2019, termed...
Background & AimsHepatitis B virus (HBV) coinfection is common among people living with HIV (PLWH) and the most important cause of hepatocellular carcinoma (HCC). Whereas risk prediction tools for HCC exist patients HBV monoinfection, they have not been evaluated in PLWH. We performed an external validation PAGE-B HIV/HBV coinfection.MethodsWe included PLWH a positive HBsAg without before starting tenofovir from four European cohorts, estimated predictive performance on occurrence over 15...
Autoantibodies neutralizing type I interferons (IFN-Is; IFNα or IFNω) exacerbate severe viral disease, but specific treatments are unavailable. With footprint profiling, we delineate two dominant IFN-I faces commonly recognized by autoantibody–containing plasmas from aged individuals with HIV-1 and COVID-19. These overlap regions independently essential for engaging the IFNAR1/IFNAR2 heterodimer, efficiently block interaction of both receptor subunits in vitro. In contrast, non-neutralizing...
Abstract Objectives: HIV 'treatment as prevention' (TasP) describes early treatment of HIV-infected patients intended to reduce viral load and transmission. Crucial assumptions for estimating TasP's effectiveness are the underlying estimates transmission risk. We aimed determine risk during primary infection, relation load. Design: A systematic review meta-analysis. Methods: searched PubMed Embase databases studies that established a relationship between risk, or infection in...
Hepatitis C (HCV) is a leading cause of morbidity and mortality in people who live with HIV. In many countries, access to direct acting antiviral agents treat HCV restricted individuals advanced liver disease (METAVIR stage F3 or F4). Our goal was estimate the long term impact deferring treatment for men have sex (MSM) are coinfected HIV often multiple risk factors progression.We developed an individual-based model progression HIV/HCV MSM. We estimated liver-related as well median time spent...
Abstract Background In 2016, the World Health Organization (WHO) introduced global targets for elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide HCV micro-elimination program among men who have sex with (MSM) living human immunodeficiency (HIV) from Swiss HIV Cohort Study (SHCS) to test whether WHO goals are achievable in this population. Methods During phase A (10/2015–06/2016), we performed population-based and systematic screening HCV-RNA MSM SHCS. B...
Treatment as prevention depends on retaining HIV-infected patients in care. We investigated the effect HIV transmission of bringing lost to follow-up (LTFU) back into care.Mathematical model.Stochastic mathematical model cohorts 1000 antiretroviral therapy, based data from 2 clinics Lilongwe, Malawi. calculated cohort viral load (sum individual mean loads each year) and used a relationship between probability estimate number new infections. simulated 4 scenarios: "no LTFU" (all stay care),...
Initiation criteria and pediatric antiretroviral treatment regimens have changed over the past few years in South Africa. We reported worse early virological outcomes associated with use of abacavir (ABC)-based at 1 large site: here, we expand this analysis to multiple sites IeDEA-Southern Africa collaboration.Data for 9543 treatment-naïve children <16 initiation started on either stavudine/lamivudine (d4T/3TC) or ABC/3TC efavirenz (EFV) ritonavir-boosted lopinavir (LPV/r) treated 6 clinics...
Abstract Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response third dose Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 (98.1% CI, 95.9%–100.0%]) individuals with different levels immunosuppression (difference, −2.8% −6.8% 1.3%]).
Mathematical models of disease progression predict outcomes and are useful epidemiological tools for planners evaluators health interventions. The 햱 package gems is a tool that simulates in patients predicts the effect different interventions on patient outcome. Disease represented by series events (e.g., diagnosis, treatment death), displayed directed acyclic graph. vertices correspond to states edges represent events. allows simulations based generalized multistate model can be described...